Aura Biosciences Inc.

NASDAQ: AURA · Real-Time Price · USD
5.92
-0.02 (-0.34%)
At close: May 23, 2025, 3:59 PM
5.91
-0.17%
After-hours: May 23, 2025, 04:08 PM EDT

Company Description

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer.

The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology.

It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.

It also develops AU-011 in additional ocular oncology indications, including choroidal metastases.

The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Aura Biosciences Inc.
Aura Biosciences Inc. logo
Country United States
IPO Date Oct 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 106
CEO Dr. Elisabet de los Pinos Ph.D.

Contact Details

Address:
85 Bolton Street
Boston, Massachusetts
United States
Website https://www.aurabiosciences.com

Stock Details

Ticker Symbol AURA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501796
CUSIP Number 05153U107
ISIN Number US05153U1079
Employer ID 32-0271970
SIC Code 2836

Key Executives

Name Position
Dr. Elisabet de los Pinos Ph.D. Founder, Chief Executive Officer, President & Director
Amy Elazzouzi Interim Chief Financial Officer, Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer
Conor Kilroy Chief Legal Officer & Secretary
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer
Dr. Anthony Daniels M.D. Vice President & Therapeutic Area of Head Ocular Oncology
Dr. Jill J. Hopkins M.D. Chief Medical Officer & President of Research and Development
Dr. Richard Mountfield Ph.D. Senior Vice President of Regulatory Affairs & Quality
Dr. Sabine Brookman-May Senior Vice President & Therapeutic Area Head of Urologic Oncology
Patrick Nealon Senior Vice President of Clinical Development Operations

Latest SEC Filings

Date Type Title
May 20, 2025 4 Filing
May 20, 2025 4 Filing
May 19, 2025 SCHEDULE 13D/A [Amend] Filing
May 16, 2025 3 Filing
May 16, 2025 8-K Current Report
May 16, 2025 424B5 Filing
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 15, 2025 424B5 Filing
May 15, 2025 10-Q Quarterly Report
May 15, 2025 8-K Current Report